PRAS40 acts as a nodal regulator of high glucose-induced TORC1 activation in glomerular mesangial cell hypertrophy

Journal of Cellular Physiology

Volumn 225, Issue 1, 2010, Pages 27-41

  Dey, Nirmalya ^a   Ghosh Choudhury, Nandini ^a,b   Das, Falguni ^a   Li, Xiaonan ^a   Venkatesan, Balachandar ^a   Barnes, Jeffrey L ^a,b   Kasinath, Balakuntalam S ^a,b   Choudhury, Goutam Ghosh ^a,b  

^a University of Texas Health Science Center at San Antonio   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INITIATION FACTOR 4E BINDING PROTEIN 1; MULTIPROTEIN COMPLEX; PROLINE RICH AKT SUBSTRATE OF 40 KDA PROTEIN; PROLINE RICH PROTEIN; S6 KINASE; TORC1 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; HYPERGLYCEMIA; KIDNEY HYPERTROPHY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CARRIER PROTEINS; CELLS, CULTURED; ENZYME ACTIVATION; GLUCOSE; MALE; MESANGIAL CELLS; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; RIBOSOMAL PROTEIN S6 KINASES; TRANSCRIPTION FACTORS;

RAPTORES; RATTUS;

EID: 77956528177     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22186     Document Type: Article

References (87)

1. Awazu M, Omori S, Ishikura K, Hida M, Fujita H. 2003. The lack of cyclin kinase inhibitor p27(Kip1) ameliorates progression of diabetic nephropathy. J Am Soc Nephrol 14:699-708. (Pubitemid 36246014)
2. Barnes VL, Musa J, Mitchell RJ, Barnes JL. 1999. Expression of embryonic fibronectin isoform EIIIA parallels alpha-smooth muscle actin in maturing and diseased kidney. J Histochem Cytochem 47:787-798.
3. Cantley LC, Neel BG. 1999. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 96:4240-4245.
4. Caramori ML, Fioretto P, Mauer M. 2000. The need for early predictors of diabetic nephropathy risk: Is albumin excretion rate sufficient? Diabetes 49:1399-1408.
5. Chen JK, Chen J, Neilson EG, Harris RC. 2005. Role of mammalian target of rapamycin signaling in compensatory renal hypertrophy. J Am Soc Nephrol 16:1384-1391.
6. Chern JJ, Choi KW. 2002. Lobe mediates Notch signaling to control domain-specific growth in the Drosophila eye disc. Development 129:4005-4013.
7. Chiang GG, Abraham RT. 2005. Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J Biol Chem 280:25485-25490.
8. Choi KM, McMahon LP, Lawrence JC, Jr. 2003. Two motifs in the translational repressor PHAS-I required for efficient phosphorylation by mammalian target of rapamycin and for recognition by raptor. J Biol Chem 278:19667-19673.
9. Choudhury GG. 2001. Akt serine threonine kinase regulates platelet-derived growth factor-induced DNA synthesis in glomerular mesangial cells: Regulation of c-fos and p27(kip1) gene expression. J Biol Chem 276:35636-35643.
10. Choudhury GG, Wang LM, Pierce J, Harvey SA, Sakaguchi AY. 1991. A mutational analysis of phosphatidylinositol-3-kinase activation by human colony-stimulating factor-1 receptor. J Biol Chem 266:8068-8072. (Pubitemid 21906476)
11. Choudhury GG, Biswas P, Grandaliano G, Fouqueray B, Harvey SA, Abboud HE. 1994. PDGF-mediated activation of phosphatidylinositol 3 kinase in human mesangial cells. Kidney Int 46:37-47.
12. Choudhury GG, Ghosh-Choudhury N, Abboud HE. 1998. Association and direct activation of signal transducer and activator of transcription 1alpha by platelet-derived growth factor receptor. J Clin Invest 101:2751-2760.
13. Cully M, You H, Levine AJ, Mak TW. 2006. Beyond PTEN mutations: The PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 6:184-192. (Pubitemid 43292562)
14. Das F, Mahimainathan L, Ghosh-Choudhury N, Venkatesan B, Kasinath BS, Abboud HE, Ghosh Choudhury G. 2007. TGFbeta intercepts nuclear glycogen synthase kinase 3beta to inhibit PDGF-induced DNA synthesis in mesangial cells. FEBS Lett 581:5259-5267.
15. Das F, Ghosh-Choudhury N, Mahimainathan L, Venkatesan B, Feliers D, Riley DJ, Kasinath BS, Choudhury GG. 2008a. Raptor-rictor axis in TGFbeta-induced protein synthesis. Cell Signal 20:409-423.
16. Das F, Ghosh-Choudhury N, Venkatesan B, Li X, Mahimainathan L, Choudhury GG. 2008b. Akt kinase targets association of CBP with SMAD 3 to regulate TGFbeta-induced expression of plasminogen activator inhibitor-1. J Cell Physiol 214:513-527.
17. Fingar DC, Blenis J. 2004. Target of rapamycin (TOR): An integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23:3151-3171. (Pubitemid 38638827)
18. Fonseca BD, Smith EM, Lee VH, MacKintosh C, Proud CG. 2007. PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex. J Biol Chem 282:24514-24524.
19. Fonseca BD, Lee VH, Proud CG. 2008. The binding of PRAS40 to 14-3-3 proteins is not required for activation of mTORC1 signalling by phorbol esters/ERK. Biochem J 411:141-149.
20. Fraenkel M, Ketzinel-Gilad M, Ariav Y, Pappo O, Karaca M, Castel J, Berthault MF, Magnan C, Cerasi E, Kaiser N, Leibowitz G. 2008. mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes 57:945-957.
21. Frias MA, Thoreen CC, Jaffe JD, Schroder W, Sculley T, Carr SA, Sabatini DM. 2006. mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr Biol 16:1865-1870.
22. Ghosh Choudhury G, Lenin M, Calhaun C, Zhang JH, Abboud HE. 2003. PDGF inactivates forkhead family transcription factor by activation of Akt in glomerular mesangial cells. Cell Signal 15:161-170.
23. Ghosh-Choudhury N, Abboud SL, Nishimura R, Celeste A, Mahimainathan L, Choudhury GG. 2002. Requirement of BMP-2-induced phosphatidylinositol 3-kinase and Akt serine/threonine kinase in osteoblast differentiation and Smad-dependent BMP-2 gene transcription. J Biol Chem 277:33361-33368.
24. Guertin DA, Sabatini DM. 2007. Defining the role of mTOR in cancer. Cancer Cell 12:9-22.
25. Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, Moffat J, Brown M, Fitzgerald KJ, Sabatini DM. 2006. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell 11:859-871.
26. Hostetter TH. 1995. Progression of renal disease and renal hypertrophy. Annu Rev Physiol 57:263-278.
27. Hostetter TH. 2003. Hyperfiltration and glomerulosclerosis. Semin Nephrol 23:194-199.
28. Huang J, Manning BD. 2008. The TSC1-TSC2 complex: A molecular switchboard controlling cell growth. Biochem J 412:179-190.
29. Huang B, Porter G. 2005. Expression of proline-rich Akt-substrate PRAS40 in cell survival pathway and carcinogenesis. Acta Pharmacol Sin 26:1253-1258. (Pubitemid 41406643)
30. Huang HC, Preisig PA. 2000. G1 kinases and transforming growth factor-beta signaling are associated with a growth pattern switch in diabetes-induced renal growth. Kidney Int 58:162-172.
31. Inoki K. 2008. Role of TSC-mTOR pathway in diabetic nephropathy. Diabetes Res Clin Pract 82:S59-S62.
32. Inoki K, Zhu T, Guan KL. 2003. TSC2 mediates cellular energy response to control cell growth and survival. Cell 115:577-590.
33. Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, Huang Q, Qin J, Su B. 2006. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127:125-137.
34. Kanwar YS, Wada J, Sun L, Xie P, Wallner EI, Chen S, Chugh S, Danesh FR. 2008. Diabetic nephropathy: Mechanisms of renal disease progression. Exp Biol Med (Maywood) 233:4-11.
35. Kasinath BS, Mariappan MM, Sataranatarajan K, Lee MJ, Feliers D. 2006. mRNA translation: Unexplored territory in renal science. J Am Soc Nephrol 17:3281-3292.
36. Kasinath BS, Mariappan MM, Sataranatarajan K, Lee MJ, Ghosh Choudhury G, Feliers D. 2008. Novel mechanisms of protein synthesis in diabetic nephropathy - Role of mRNA translation. Rev Endocr Metab Disord 9:255-266.
37. Kasinath BS, Feliers D, Sataranatarajan K, Ghosh Choudhury G, Lee MJ, Mariappan MM. 2009. Regulation of mRNA translation in renal physiology and disease. Am J Physiol Renal Physiol 297:F1153-F1165.
38. Kong M, Mounier C, Wu J, Posner BI. 2000. Epidermal growth factor-induced phosphatidylinositol 3-kinase activation and DNA synthesis. Identification of Grb2-associated binder 2 as the major mediator in rat hepatocytes. J Biol Chem 275:36035-36042.
39. Kovacina KS, Park GY, Bae SS, Guzzetta AW, Schaefer E, Birnbaum MJ, Roth RA. 2003. Identification of a proline-rich Akt substrate as a 14-3-3 binding partner. J Biol Chem 278:10189-10194. (Pubitemid 36800278)
40. Lee CH, Inoki K, Guan KL. 2007a. mTOR pathway as a target in tissue hypertrophy. Annu Rev Pharmacol Toxicol 47:443-467.
41. Lee MJ, Feliers D, Mariappan MM, Sataranatarajan K, Mahimainathan L, Musi N, Foretz M, Viollet B, Weinberg JM, Choudhury GG, Kasinath BS. 2007b. A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy. Am J Physiol Renal Physiol 292:F617-F627.
42. Lehmann R, Schleicher ED. 2000. Molecular mechanism of diabetic nephropathy. Clin Chim Acta 297:135-144.
43. Loewith R, Jacinto E, Wullschleger S, Lorberg A, Crespo JL, Bonenfant D, Oppliger W, Jenoe P, Hall MN. 2002. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 10:457-468. (Pubitemid 35284167)
44. Long X, Lin Y, Ortiz-Vega S, Yonezawa K, Avruch J. 2005. Rheb binds and regulates the mTOR kinase. Curr Biol 15:702-713.
45. Ma XM, Blenis J. 2009. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 10:307-318.
46. Mahimainathan L, Choudhury GG. 2004. Inactivation of platelet-derived growth factor receptor by the tumor suppressor PTEN provides a novel mechanism of action of the phosphatase. J Biol Chem 279:15258-15268.
47. Mahimainathan L, Ghosh-Choudhury N, Venkatesan BA, Danda RS, Choudhury GG. 2005. EGF stimulates mesangial cell mitogenesis via PI3-kinase-mediated MAPK-dependent and AKT kinase-independent manner: Involvement of c-fos and p27Kip1. Am J Physiol Renal Physiol 289:F72-F82.
48. Mahimainathan L, Das F, Venkatesan B, Choudhury GG. 2006. Mesangial cell hypertrophy by high glucose is mediated by downregulation of the tumor suppressor PTEN. Diabetes 55:2115-2125.
49. Mahimainathan L, Ghosh-Choudhury N, Venkatesan B, Das F, Mandal CC, Dey N, Habib SL, Kasinath BS, Abboud HE, Ghosh Choudhury G. 2009. TSC2 deficiency increases PTEN via HIF1alpha. J Biol Chem 284:27790-27798.
50. Mandal CC, Ghosh Choudhury G, Ghosh-Choudhury N. 2009. Phosphatidylinositol 3 kinase/Akt signal relay cooperates with smad in bone morphogenetic protein-2-induced colony stimulating factor-1 (CSF-1) expression and osteoclast differentiation. Endocrinology 150:4989-4998.
51. Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC. 1984. Structural-functional relationships in diabetic nephropathy. J Clin Invest 74:1143-1155.
52. McBride SM, Perez DA, Polley MY, Vandenberg SR, Smith JS, Zheng S, Lamborn KR, Wiencke JK, Chang SM, Prados MD, Berger MS, Stokoe D, Haas-Kogan DA. 2009. Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival. J Neurooncol. 97:33-40.
53. Nojima H, Tokunaga C, Eguchi S, Oshiro N, Hidayat S, Yoshino K, Hara K, Tanaka N, Avruch J, Yonezawa K. 2003. The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J Biol Chem 278:15461-15464.
54. Oldham S, Montagne J, Radimerski T, Thomas G, Hafen E. 2000. Genetic and biochemical characterization of dTOR, the Drosophila homolog of the target of rapamycin. Genes Dev 14:2689-2694. (Pubitemid 32531195)
55. Oshiro N, Takahashi R, Yoshino K, Tanimura K, Nakashima A, Eguchi S, Miyamoto T, Hara K, Takehana K, Avruch J, Kikkawa U, Yonezawa K. 2007. The proline-rich Akt substrate of 40kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1. J Biol Chem 282:20329-20339.
56. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS. 2003. Regression of microalbuminuria in type 1 diabetes. N Engl J Med 348:2285-2293.
57. Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM, Gray NS, Sabatini DM. 2009. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 137:873-886.
58. Quon MJ, Chen H, Ing BL, Liu ML, Zarnowski MJ, Yonezawa K, Kasuga M, Cushman SW, Taylor SI. 1995. Roles of 1-phosphatidylinositol 3-kinase and ras in regulating translocation of GLUT4 in transfected rat adipose cells. Mol Cell Biol 15:5403-5411.
59. Rush J, Moritz A, Lee KA, Guo A, Goss VL, Spek EJ, Zhang H, Zha XM, Polakiewicz RD, Comb MJ. 2005. Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat Biotechnol 23:94-101.
60. Saito A, Narasimhan P, Hayashi T, Okuno S, Ferrand-Drake M, Chan PH. 2004. Neuroprotective role of a proline-rich Akt substrate in apoptotic neuronal cell death after stroke: Relationships with nerve growth factor. J Neurosci 24:1584-1593.
61. Sakaguchi M, Isono M, Isshiki K, Sugimoto T, Koya D, Kashiwagi A. 2006. Inhibition of mTOR signaling with rapamycin attenuates renal hypertrophy in the early diabetic mice. Biochem Biophys Res Commun 340:296-301. (Pubitemid 41827680)
62. Sancak Y, Thoreen CC, Peterson TR, Lindquist RA, Kang SA, Spooner E, Carr SA, Sabatini DM. 2007. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell 25:903-915.
63. Sancak Y, Peterson TR, Shaul YD, Lindquist RA, Thoreen CC, Bar-Peled L, Sabatini DM. 2008. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 320:1496-1501.
64. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM. 2004. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14:1296-1302.
65. Sataranatarajan K, Mariappan MM, Lee MJ, Feliers D, Choudhury GG, Barnes JL, Kasinath BS. 2007. Regulation of elongation phase of mRNA translation in diabetic nephropathy: Amelioration by rapamycin. Am J Pathol 171:1733-1742.
66. Satriano J. 2007. Kidney growth, hypertrophy and the unifying mechanism of diabetic complications. Amino Acids 33:331-339. (Pubitemid 47222975)
67. Schalm SS, Blenis J. 2002. Identification of a conserved motif required for mTOR signaling. Curr Biol 12:632-639.
68. Schalm SS, Fingar DC, Sabatini DM, Blenis J. 2003. TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function. Curr Biol 13:797-806.
69. Senthil D, Choudhury GG, Abboud HE, Sonenberg N, Kasinath BS. 2002. Regulation of protein synthesis by IGF-I in proximal tubular epithelial cells. Am J Physiol Renal Physiol 283:F1226-F1236.
70. Shiota C, Woo JT, Lindner J, Shelton KD, Magnuson MA. 2006. Multiallelic disruption of the rictor gene in mice reveals that mTOR complex 2 is essential for fetal growth and viability. Dev Cell 11:583-589. (Pubitemid 44430900)
71. Shultz PJ, DiCorleto PE, Silver BJ, Abboud HE. 1988. Mesangial cells express PDGF mRNAs and proliferate in response to PDGF. Am J Physiol 255:F674-F684.
72. Singh A, Chan J, Chern JJ, Choi KW. 2005. Genetic interaction of Lobe with its modifiers in dorsoventral patterning and growth of the Drosophila eye. Genetics 171:169-183.
73. Takahashi T, Hara K, Inoue H, Kawa Y, Tokunaga C, Hidayat S, Yoshino K, Kuroda Y, Yonezawa K. 2000. Carboxyl-terminal region conserved among phosphoinositide-kinase-related kinases is indispensable for mTOR function in vivo and in vitro. Genes Cells 5:765-775.
74. Thedieck K, Polak P, Kim ML, Molle KD, Cohen A, Jeno P, Arrieumerlou C, Hall MN. 2007. PRAS40 and PRR5-like protein are new mTOR interactors that regulate apoptosis. PLoS One 2:e1217.
75. Vander Haar E, Lee SI, Bandhakavi S, Griffin TJ, Kim DH. 2007. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol 9:316-323.
76. Venkatesan BA, Mahimainathan L, Ghosh-Choudhury N, Gorin Y, Bhandari B, Valente AJ, Abboud HE, Choudhury GG. 2006. PI 3 kinase-dependent Akt kinase and PKCepsilon independently regulate interferon-gamma-induced STAT1alpha serine phosphorylation to induce monocyte chemotactic protein-1 expression. Cell Signal 18:508-518.
77. Venkatesan B, Mahimainathan L, Das F, Ghosh-Choudhury N, Ghosh Choudhury G. 2007. Downregulation of catalase by reactive oxygen species via PI 3 kinase/Akt signaling in mesangial cells. J Cell Physiol 211:457-467. (Pubitemid 46580099)
78. Venkatesan B, Ghosh-Choudhury N, Das F, Mahimainathan L, Kamat A, Kasinath BS, Abboud HE, Choudhury GG. 2008. Resveratrol inhibits PDGF receptor mitogenic signaling in mesangial cells: Role of PTP1B. FASEB J 22:3469-3482.
79. Wang YH, Huang ML. 2009. Reduction of Lobe leads to TORC1 hypoactivation that induces ectopic Jak/STAT signaling to impair Drosophila eye development. Mech Dev 126:781-790.
80. Wang L, Harris TE, Roth RA, Lawrence JC, Jr. 2007. PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. J Biol Chem 282:20036-20044.
81. Wang L, Harris TE, Lawrence JC, Jr. 2008. Regulation of proline-rich Akt substrate of 40 kDa (PRAS40) function by mammalian target of rapamycin complex 1 (mTORC1)-mediated phosphorylation. J Biol Chem 283:15619-15627.
82. Wolf G, Ziyadeh FN. 1999. Molecular mechanisms of diabetic renal hypertrophy. Kidney Int 56:393-405. (Pubitemid 29353136)
83. Woo SY, Kim DH, Jun CB, Kim YM, Haar EV, Lee SI, Hegg JW, Bandhakavi S, Griffin TJ, Kim DH. 2007. PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling. J Biol Chem 282:25604-25612.
84. Wullschleger S, Loewith R, Hall MN. 2006. TOR signaling in growth and metabolism. Cell 124:471-484.
85. Yang Y, Wang J, Qin L, Shou Z, Zhao J, Wang H, Chen Y, Chen J. 2007. Rapamycin prevents early steps of the development of diabetic nephropathy in rats. Am J Nephrol 27:495-502. (Pubitemid 47482007)
86. Zhang F, Beharry ZM, Harris TE, Lilly MB, Smith CD, Mahajan S, Kraft AS. 2009. PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells. Cancer Biol Ther 8:846-853.
87. Ziyadeh FN, Wolf G. 2008. Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr Diabetes Rev 4:39-45.